IntegraGen Announces Leading U.S. Cancer Center to Use MERCURY™ Cloud-based Tool for Oncology Sequencing Data Interpretatio...
March 26 2020 - 1:00PM
Business Wire
Regulatory News:
IntegraGen (Paris:ALINT), a company specializing in the
transformation of data from biological samples into genomic
information and diagnostic tools for oncology, today announced
Dana-Farber Cancer Institute will utilize the company’s MERCURY™
cloud-based software as part of their analysis and reporting
process for sequencing data obtained from tumors of cancer
patients. Dana-Farber plans to utilize MERCURY to assist in the
analysis of sequencing data obtained from small and large targeted
gene sequencing panels as well as data derived from whole exome and
genome sequencing.
“Genomic profiling of tumors can assist in the identification of
pathogenic molecular alterations which drive a patient’s cancer and
enable the implementation of precision medicine-based approaches to
treatment,” stated Annette S. Kim M.D., Ph.D., Co-Director of the
Dana-Farber Cancer Institute’s new Interpretive Genomics Program
within the Department of Oncologic Pathology. The program is
Co-Directed by Keith L. Ligon, MD PhD, Director of the Dana-Farber
Center for Patient Derived Models. “MERCURY provides us with a tool
to rapidly interpret large scale and complex genomic sequencing
data with the added ability of customization to meet our specific
analysis and reporting needs to support clinical research and
clinical trials.”
“IntegraGen is excited about Dana-Faber’s decision to utilize
MERCURY and look forward to interacting with another world leader
in cancer care related to the utilization of our cloud-based
bioinformatic tools,” said Larry Yost, General Manager of
IntegraGen, Inc. “We are convinced that the use of MERCURY will aid
in the better understanding of the etiology of a patient’s cancer
and assist with the realization of the benefits of precision
medicine by transforming large-scale sequencing data into
actionable results. We are also looking forward to continuing the
development and expansion of our genomic interpretation software
tools in North America.”
MERCURY is a user-friendly genomic interpretation tool for
oncology designed to assist pathologists and oncologists to rapidly
transform raw data obtained via high-throughput sequencing into a
clinical molecular report for clinical and research use. The
cloud-based tool minimizes the complexity, time and cost associated
with the clinical interpretation and identification of variants
that may be of interest in the therapeutic management of patients.
MERCURY utilizes the Google Cloud technology to ensure a secure
environment for data analysis and storage which is compliant with
the latest information security requirements.
About IntegraGen
IntegraGen is a company specializing in the analysis of the
human genome and performs adaptive and quickly interpretable
analyses for academic and private laboratories. For the management
of cancers, which are characterized by a genetic disruption of
cells, IntegraGen provides researchers and doctors with universal
and individualized therapeutic guidance tools allowing them to
adapt the treatment to the patient's genetic profile.
IntegraGen has forty-six employees and generated revenue of €
8.3 million in 2019. Based in the Génopole d'Evry, IntegraGen is
also located in the United States in Cambridge, MA. IntegraGen is
listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo:
ALINT - Eligible PEA-PME).
For more information, visit www.integragen.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200326005546/en/
Contacts IntegraGen Bernard COURTIEU President and
CEO
Laurence RIOT LAMOTTE Chief Financial Officer
contact@integragen.com Tel: +33 (0)1 60 91 09 00
NewCap Investor and Media Relations Louis-Victor
DELOUVRIER integragen@newcap.eu Tel: +33 (0)1 44 71 98 53
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024